Accessibility Menu
Arrow-Thin-Down
S&P 500
6,783.32
-1.0%
-68.65
Arrow-Thin-Down
DJI
47,032.71
-0.6%
-303.97
Arrow-Thin-Down
NASDAQ
23,409.95
-1.8%
-424.77
Arrow-Thin-Down
Bitcoin
$101,369.00
-5.2%
-$5,600.48
Arrow-Thin-Down
AAPL
$270.42
+0.5%
+$1.37
Arrow-Thin-Down
AMZN
$249.26
-1.9%
-$4.74
Arrow-Thin-Down
GOOG
$277.96
-2.2%
-$6.16
Arrow-Thin-Down
META
$629.68
-1.3%
-$8.03
Arrow-Thin-Down
MSFT
$511.56
-1.1%
-$5.47
Arrow-Thin-Down
NVDA
$199.85
-3.4%
-$7.03
Arrow-Thin-Down
TSLA
$448.03
-4.3%
-$20.34
Daily Stock GainersDaily Stock LosersMost Active Stocks
Talis Biomedical Stock Quote

Talis Biomedical (OTC: TLIS)

$1.60
(0.0%)
+0.00
Price as of October 30, 2025, 4:49 p.m. ET

KEY DATA POINTS

Current Price
$1.60
Daily Change
(0.0%) +$0.00
Day's Range
$1.60 - $1.60
Previous Close
$1.60
Open
$1.60
Beta
0.70
Volume
75
Average Volume
217
Sector
Health Care
Market Cap
50.7M
Market Cap / Employee
$1.60M
52wk Range
$1.04 - $2.00
Revenue
-
Gross Margin
-
Dividend Yield
N/A
EPS
$0.00
CAPs Rating
-
Industry
Healthcare Equipment and Supplies

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Talis Biomedical Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
TLIS-6.98%N/AN/A-100%
S&P+19.61%+98.99%+14.75%+74%

Talis Biomedical Company Info

Talis Biomedical Corp. develops and commercializes innovative products that are designed to enable accurate, reliable, low cost and rapid molecular testing for infectious diseases. The company was founded on June 26, 2013 and is headquartered in Redwood City, CA.

Financial Health

General

Q2 2024YOY Change
Revenue$0.00M0.0%
Gross Profit-$0.08M0.0%
Gross Margin-267.12%0.0%
Market Cap$274.46M0.0%
Market Cap / Employee$2.77M0.0%
Employees990.0%
Net Income-$8.85M0.0%
EBITDA-$8.49M0.0%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2024YOY Change
Net Cash$59.87M0.0%
Accounts Receivable$0.00M0.0%
Inventory00.0%

Liabilities

Q2 2024YOY Change
Long Term Debt$15.88M0.0%
Short Term Debt$2.92M0.0%

Ratios

Q2 2024YOY Change
Return On Assets-52.13%0.0%
Return On Invested Capital-30.02%0.0%

Cash Flow

Q2 2024YOY Change
Free Cash Flow-$11.33M0.0%
Operating Free Cash Flow-$11.33M0.0%

Valuation

MetricQ4 2023Q1 2024Q2 2024YoY Change
Price to Book2.894.014.84-
Price to Sales32.9545.8152.62-
Price to Tangible Book Value2.894.014.84-
Enterprise Value to EBITDA3.043.962.98-
Return on Equity-63.3%-68.6%-70.5%-
Total Debt$19.67M$19.24M$18.80M-

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services